Search Result

Results for "

B7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD276/B7-H3 (15) 5-HT Receptor (5) ADC Antibody (4) ADC Linker (1) ADC Payload (1) Akt (1) Amyloid-β (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (5) APC (1) Apoptosis (5) Autophagy (6) Bacterial (6) Carboxylesterase (CES) (2) CD28 (8) CD3 (2) CD47 (1) CD74 (1) Cholinesterase (ChE) (2) COX (2) CTLA-4 (5) Cytochrome P450 (2) Dihydrofolate reductase (DHFR) (1) DNA/RNA Synthesis (1) Drug Derivative (2) Drug Metabolite (3) EGFR (3) Endogenous Metabolite (9) Environmental Pollutants (1) ERK (1) Estrogen Receptor/ERR (1) FAK (1) Fc Receptor (FcR) (1) Fungal (1) IFNAR (2) Interleukin Related (5) Isotope-Labeled Compounds (3) Keap1-Nrf2 (1) LAG-3 (2) MDM-2/p53 (1) MHC (1) Microtubule/Tubulin (1) MMP (1) mTOR (1) NF-κB (2) NO Synthase (3) Oxytocin Receptor (1) p38 MAPK (3) PD-1/PD-L1 (17) Phosphodiesterase (PDE) (5) PKC (1) RANKL/RANK (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) RXFP Receptor (2) SDCBP (1) Sirtuin (2) Small Interfering RNA (siRNA) (8) SOD (2) STAT (1) Tau Protein (2) Tim3 (1) TNF Receptor (4) Topoisomerase (3) Transmembrane Glycoprotein (6) UGT (7) Vasopressin Receptor (1) VEGFR (1) VISTA (2) α-synuclein (1)
By Research Areas:	Cancer (72) Cardiovascular Disease (3) Infection (11) Inflammation/Immunology (43) Metabolic Disease (15) Neurological Disease (15)
Click Chemistry:	Azide (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (4) siRNAs (8)

131

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

132

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: CD276/B7-H3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0511

Biotin Maximum Cited Publications 26 Publications Verification Vitamin B7; Vitamin H; D-Biotin	Environmental Pollutants Endogenous Metabolite	Metabolic Disease
Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) Maximum Cited Publications 15 Publications Verification	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9966

Enoblituzumab 1 Publications Verification MGA271	CD276/B7-H3	Cancer
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human *B7-H3* protein, a member of the B7 family of immune regulators .

HY-P99367

Ifinatamab DS-7300a Antibody; MABX-9001A Antibody	CD276/B7-H3	Inflammation/Immunology Cancer
Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur .

HY-108829

Abatacept 1 Publications Verification CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a *B7-H3*-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99132

Anti-Mouse CTLA-4 Antibody (9D9) 2 Publications Verification	CTLA-4	Inflammation/Immunology Cancer
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 ⁺ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-155747

FDW028 1 Publications Verification	Autophagy Akt mTOR	Cancer
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized *B7-H3* monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P10728

B7-33	RXFP Receptor ERK	Cardiovascular Disease Inflammation/Immunology
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .

HY-P1698

Reltecimod AB-103	Bacterial CD28	Infection Inflammation/Immunology Cancer
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .

HY-108829A

Abatacept (powder) 1 Publications Verification CTLA4lg (powder); BMS-188667 (powder); Orencia	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-171689

Puxitatug samrotecan AZD 8205; P-Sam	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Puxitatug samrotecan (AZD 8205) is a *B7-H4*-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR ⁺/HER2 ^- breast cancer .

HY-P991537

Risvutatug HS-20093 Antibody; GSK5764227 Antibody	ADC Antibody CD276/B7-H3	Cancer
HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting *B7-H3, which can be used to synthesize the ADC* HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

HY-P99157

Omburtamab	CD276/B7-H3	Cancer
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to *B7-H3* highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to *CD276/B7-H3* with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-118700

2-Iminobiotin Guanidinobiotin	NO Synthase	Neurological Disease
2-Iminobiotin (Guanidinobiotin) is a biotin (vitamin H or B7) analog. 2-Iminobiotin is a reversible nitric oxide synthases inhibitor with K_is of 21.8 and 37.5μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .

HY-102090

B7/CD28 interaction inhibitor 1	CD28	Inflammation/Immunology
B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC₅₀ of 50 nM .

HY-P99145A

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.

HY-B0511R

Biotin (Standard) Vitamin B7 (Standard); Vitamin H (Standard); D-Biotin (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
Biotin (Standard) is the analytical standard of Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-P991703

Mocertatug GSK5733584 antibody; HS-20089 antibody; hu2F7	CD276/B7-H3	Cancer
Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting *B7-H4/VTCN1*. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280) .

HY-P990059

Puxitatug INT-016; AZD8205 Antibody	ADC Antibody CD276/B7-H3	Cancer
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting *VTCN1/B7-H4*. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .

HY-B0511S3

Biotin-13C5 Vitamin B7-¹³C₅; Vitamin H-¹³C₅; D-Biotin-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Biotin- ¹³C₅ (Vitamin B7- ¹³C₅) is ¹³C labeled Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-124813

PDZ1i 113B7	FAK EGFR MMP NF-κB SDCBP	Cancer
PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .

HY-P99242

Alsevalimab 1 Publications Verification	CD276/B7-H3	Cancer
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against *B7-H4. Alsevalimab blocks the binding of the B7-H4* protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .

HY-P991449

LY3415244	PD-1/PD-L1 Tim3	Cancer
LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .

HY-P990127

Anti-Mouse CD80/B7-1 Antibody (RM80)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse *CD80/B7-1* IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (T_RM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .

HY-P990260

Anti-Mouse CD86/B7-2 Antibody (GL-1)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *CD86/B7-2*. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation .

HY-P99141

Anti-Mouse LAG-3 Antibody (C9B7W)	LAG-3	Inflammation/Immunology Cancer
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 ⁺ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .

HY-177542

Emiltatug ledadotin Emi-Le; XMT-1660		Cancer
Emiltatug ledadotin (Emi-Le; XMT-1660) is a *B7-H4*-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of *B7-H4*-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with *B7-H4* overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .

HY-148696A

Gly-Cyclopropane-Exatecan	ADC Payload Topoisomerase	Cancer
Gly-Cyclopropane-Exatecan involves in the synthesis of anti-B7-H4 ADC, containing Exatecan (HY-13631), a DNA Topoisomerase I inhibitor. Gly-Cyclopropane-Exatecan participated in the formation of the ADC hu2F7-Exatecan (compound 34), which showed antitumor activity in vivo and in vitro .

HY-118700A

2-Iminobiotin hydrobromide Guanidinobiotin hydrobromide	NO Synthase	Neurological Disease
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K_is of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin hydrobromide superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .

HY-P990279

Anti-Mouse CD276/B7-H3 Antibody (MJ18)	CD276/B7-H3 Apoptosis STAT	Inflammation/Immunology Cancer
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse *CD276/B7-H3* IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1* Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-B0511A

Biotin sodium Vitamin B7 sodium; Vitamin H sodium; D-Biotin sodium	Endogenous Metabolite	Metabolic Disease
Biotin (Vitamin B7) sodium is a water-soluble B vitamin and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin sodium is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-P991223

NC762	Transmembrane Glycoprotein TNF Receptor	Cancer
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing *B7-H4*. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .

HY-145636

Vobramitamab duocarmazine AEX4089DC1; MGC018	Antibody-Drug Conjugates (ADCs)	Cancer
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .

HY-P990136

Anti-Monkey/Human CD28 Antibody (CD28.2)	CD28	Inflammation/Immunology
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to monkey/human CD28. Anti-Monkey/Human CD28 Antibody (CD28.2) can block CD28 signaling. Anti-Monkey/Human CD28 Antibody (CD28.2) can be used for the research of immunology .

HY-P10325

Kalata B7	Vasopressin Receptor Oxytocin Receptor	Cardiovascular Disease
Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V_1a receptors .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of *B7H4*-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of *B7H4*-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-P990623

MDX-1105 BMS-936559	PD-1/PD-L1	Inflammation/Immunology
MDX-1105 is a human antibody expressed in CHO that targets *B7-H1/PD-L1/CD274*. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-175780

CD28-IN-1	CD28 IFNAR TNF Receptor Interleukin Related	Cancer
CD28-IN-1 (Compound 19MS-5) is a CD28 inhibitor with a K_D of 12.48  μM. CD28-IN-1 has a superior binding capacity to CD28 and potently inhibits CD28-B7 interactions. CD28-IN-1 inhibits CD28-driven immune activation and suppresses cytokine (IFN-γ, IL-2 and TNF-α) production in primary human T cells co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 can be used for tumor immunity research .

HY-B0511S

Biotin-d2-1 Vitamin B7 d₂-1; Vitamin H d₂-1; D-Biotin d₂-1	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Biotin-d₂-1 is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.

HY-N13987

Arylomycin B7	Antibiotic Bacterial	Infection
Arylomycin B7 is a lipohexapeptide antibiotic against Gram-positive bacteria .

HY-P991447

Anti-VSIR/VISTA Antibody (SG7)	VISTA	Cancer
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting *VISTA/B7-H5*. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990170

Anti-Mouse PD-L2/B7-DC Antibody (TY25)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC* Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation .

Cat. No.	Product Name	Type

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dye

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

Cat. No.	Product Name	Target	Research Area

HY-P10728

B7-33	RXFP Receptor ERK	Cardiovascular Disease Inflammation/Immunology
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .

HY-P1698

Reltecimod AB-103	Bacterial CD28	Infection Inflammation/Immunology Cancer
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .

HY-P10325

Kalata B7	Vasopressin Receptor Oxytocin Receptor	Cardiovascular Disease
Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V_1a receptors .

HY-P11246

A13:B7-24-GG	RXFP Receptor	Metabolic Disease
A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a K_i value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (K_i = 602.56 nM) and an inhibitory effect on cAMP (EC₅₀) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC₅₀ of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .

HY-106156

Allotrap 07	MHC	Cardiovascular Disease Inflammation/Immunology
Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival .

HY-P10339

SMCY peptide	Peptides	Inflammation/Immunology
SMCY peptide inhibits the binding of iodinated standard peptide to *HLA-B7* with an IC₅₀ of 34 nM. As an epitope of the H-Y antigen, SMCY peptide can be presented by the HLA-B7 molecule and recognized by specific T cells, leading to transplant rejection .

HY-P1698B

Reltecimod TFA AB-103 TFA	Bacterial CD28	Infection Inflammation/Immunology Cancer
Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) Maximum Cited Publications 15 Publications Verification	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9966

Enoblituzumab 1 Publications Verification MGA271	CD276/B7-H3	Cancer
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human *B7-H3* protein, a member of the B7 family of immune regulators .

HY-P99367

Ifinatamab DS-7300a Antibody; MABX-9001A Antibody	CD276/B7-H3	Inflammation/Immunology Cancer
Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur .

HY-108829

Abatacept 1 Publications Verification CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a *B7-H3*-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99132

Anti-Mouse CTLA-4 Antibody (9D9) 2 Publications Verification	CTLA-4	Inflammation/Immunology Cancer
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 ⁺ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized *B7-H3* monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-108829A

Abatacept (powder) 1 Publications Verification CTLA4lg (powder); BMS-188667 (powder); Orencia	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P991537

Risvutatug HS-20093 Antibody; GSK5764227 Antibody	ADC Antibody CD276/B7-H3	Cancer
HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting *B7-H3, which can be used to synthesize the ADC* HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

HY-P99157

Omburtamab	CD276/B7-H3	Cancer
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to *B7-H3* highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to *CD276/B7-H3* with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99145A

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.

HY-P991703

Mocertatug GSK5733584 antibody; HS-20089 antibody; hu2F7	CD276/B7-H3	Cancer
Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting *B7-H4/VTCN1*. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280) .

HY-P990059

Puxitatug INT-016; AZD8205 Antibody	ADC Antibody CD276/B7-H3	Cancer
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting *VTCN1/B7-H4*. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-P99242

Alsevalimab 1 Publications Verification	CD276/B7-H3	Cancer
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against *B7-H4. Alsevalimab blocks the binding of the B7-H4* protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .

HY-P991449

LY3415244	PD-1/PD-L1 Tim3	Cancer
LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .

HY-P990127

Anti-Mouse CD80/B7-1 Antibody (RM80)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse *CD80/B7-1* IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (T_RM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .

HY-P990260

Anti-Mouse CD86/B7-2 Antibody (GL-1)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *CD86/B7-2*. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation .

HY-P99141

Anti-Mouse LAG-3 Antibody (C9B7W)	LAG-3	Inflammation/Immunology Cancer
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 ⁺ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .

HY-P990279

Anti-Mouse CD276/B7-H3 Antibody (MJ18)	CD276/B7-H3 Apoptosis STAT	Inflammation/Immunology Cancer
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse *CD276/B7-H3* IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1* Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-P991223

NC762	Transmembrane Glycoprotein TNF Receptor	Cancer
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing *B7-H4*. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .

HY-P990136

Anti-Monkey/Human CD28 Antibody (CD28.2)	CD28	Inflammation/Immunology
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to monkey/human CD28. Anti-Monkey/Human CD28 Antibody (CD28.2) can block CD28 signaling. Anti-Monkey/Human CD28 Antibody (CD28.2) can be used for the research of immunology .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of *B7H4*-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of *B7H4*-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-P990623

MDX-1105 BMS-936559	PD-1/PD-L1	Inflammation/Immunology
MDX-1105 is a human antibody expressed in CHO that targets *B7-H1/PD-L1/CD274*. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990341

Anti-B7-H4/VTCN1 Antibody	Inhibitory Antibodies	Inflammation/Immunology
Anti-B7-H4/VTCN1 Antibody is a CHO-expressed human antibody that targets *B7-H4/VTCN1. The Anti-B7-H4/VTCN1* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991447

Anti-VSIR/VISTA Antibody (SG7)	VISTA	Cancer
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting *VISTA/B7-H5*. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990170

Anti-Mouse PD-L2/B7-DC Antibody (TY25)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC* Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation .

HY-P990342

Anti-B7-H6/NCR3LG1 Antibody	Inhibitory Antibodies	Inflammation/Immunology
The Anti-B7-H6/NCR3LG1 Antibody is a CHO-expressed human antibody that targets *B7-H6/NCR3LG1. The Anti-B7-H6/NCR3LG1* Antibody features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa.

HY-P991092

IBI-334	EGFR CD276/B7-H3	Cancer
IBI-334 is a bispecific *B7-H3* and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 shows antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors .

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .

HY-P990340

Anti-B7-H3/CD276 Antibody	CD276/B7-H3	Inflammation/Immunology
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting *B7-H3/CD276. Anti-B7-H3/CD276* Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990128

Anti-Rat CD80/B7-1 Antibody (3H5)	CD28	Inflammation/Immunology Cancer
Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat *CD80/B7-1*. Anti-Rat CD80/B7-1 Antibody (3H5) blocks a costimulatory signals for T-cell activation. Anti-Rat CD80/B7-1 Antibody (3H5) can be used for the researches of cancer and immunology .

HY-P991563

Anti-CEACAM5 Antibody (A5B7)	Inhibitory Antibodies	Others
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. Anti-CEACAM5 Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991355

PDL-GEX	PD-1/PD-L1	Cancer
PDL-GEX is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274*. PDL-GEX can be used in cancer research .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274*. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274*. STT-001 can be used in Solid tumours research .

HY-P991421

W0180	VISTA	Cancer
W0180 is a human IgG1 monoclonal antibody (mAb) targeting *VISTA/B7-H5*. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274*. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P990986

Efdelikofusp alfa	Interleukin Related	Inflammation/Immunology Cancer
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-P990992

Efzilonkofusp alfa GI-102	Interleukin Related	Inflammation/Immunology Cancer
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-P990456

Anti-Integrin b7/ITGB7 Antibody	Inhibitory Antibodies	Inflammation/Immunology
Anti-Integrin b7/ITGB7 Antibody is a CHO-expressed humanized antibody that targets Integrin b7/ITGB7. Anti-Integrin b7/ITGB7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Integrin b7/ITGB7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991777

Anti-Mouse CD86/B7-2 Antibody (2D10)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD86/B7-2 Antibody (2D10) reacts with mouse CD86 (B7-2). Anti-Mouse CD86/B7-2 Antibody (2D10) reduces IL-4 production in T cells. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .

HY-P992193

Anti-B7-H7 Antibody	APC	Inflammation/Immunology
Anti-B7-H7 Antibody is a monoclonal antibody targeting HHLA2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-B7-H7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990823

Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11)	PD-1/PD-L1	Infection Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is rat-derived IgG2b κ type antibody inhibitor, targeting to *PD-L1/B7-H1. Anti-Mouse PD-L1/B7-H1* Antibody (10F.2H11) can block PD-L1/ B7-1 interactions and does not block PD-L1/PD-1 interactions. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can be used for the researches of cancer, infection, immunology and metabolic disease, such as MB49 tumor, heart graft and diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0511

Biotin Maximum Cited Publications 26 Publications Verification Vitamin B7; Vitamin H; D-Biotin	Structural Classification Immune System Disorder Microorganisms other families Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Metabolic Disease Plants Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite
Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-N0372

Licochalcone A 15+ Cited Publications	Chalcones Flavonoids Classification of Application Fields Leguminosae Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Source Classification Cancer	Autophagy
Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM) .

HY-N0235

Bakuchiol 2 Publications Verification (S)-(+)-Bakuchiol	Monophenols Classification of Application Fields Leguminosae Phenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification Cancer	Carboxylesterase (CES) p38 MAPK Autophagy UGT
Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-N0859

Schisanhenol Schizanhenol; Gomisin-K3	Structural Classification Monophenols Classification of Application Fields Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Source Classification Cancer	UGT Cholinesterase (ChE) Tau Protein SOD Sirtuin
Schisanhenol (Schizanhenol), a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits *UGT2B7* activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration .

HY-N0762

Isobavachin 5 Publications Verification	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification	Cytochrome P450 UGT p38 MAPK NF-κB NO Synthase COX Fc Receptor (FcR) RANKL/RANK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Autophagy
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and *UGT2B7. Isobavachin suppresses MAPK* activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease ^[7] .

HY-B0511R

Biotin (Standard) Vitamin B7 (Standard); Vitamin H (Standard); D-Biotin (Standard)	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Reference Standards
Biotin (Standard) is the analytical standard of Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-B0511A

Biotin sodium Vitamin B7 sodium; Vitamin H sodium; D-Biotin sodium	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Biotin (Vitamin B7) sodium is a water-soluble B vitamin and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin sodium is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-N0229R

L-Alanine (Standard) L-2-Aminopropionic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Disease markers Amino acids Endogenous metabolite Cancer Source Classification	Reference Standards Endogenous Metabolite
L-Alanine (Standard) is the analytical standard of L-Alanine. This product is intended for research and analytical applications. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system. In Vitro: The viability of both hiPSCs, 201B7 cells and ehiPSCs decrease with an increase in L-Alanine concentration, and reach 7.5±1.3% and 3.7±0.7% respectively at 1.2 M of L-Alanine. On the other hand, no decrease in the viability of hFBs and hSkMCs are observed. Although the viability of iCMs slightly decreases along with the increase of the L-Alanine concentration, viability of iCMs at 1.2 M concentration of L-Alanine, 49.4±6.9%, is significantly higher than that of undifferentiated iPSCs, 201B7 cells and ehiPSCs (p< 0.01). The viability of hiPSCs, 201B7 cells and ehiPSCs, drastically decrease even after 2 or 4 h treatment. In contrast, the viability of hFBs fails to decrease at 1, 2, and 4 h and shows a small decrease at 24 h treatment. The viability of 201B7 cells in suspension culture decreases to 11.8±6.0% following treatment with 1.2 M L-Alanine for 2 h, whereas that of hFBs is 72.9±14.2% .

HY-N13987

Arylomycin B7	Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
Arylomycin B7 is a lipohexapeptide antibiotic against Gram-positive bacteria .

HY-N7776

7-Xylosyl-10-Deacetyltaxol B 7-xylosyl-10-Deacetylpaclitaxel B	Taxus cuspidata Siebold & Zucc. Terpenoids Taxaceae Diterpenoids Plants Source Classification	Others
7-Xylosyl-10-Deacetyltaxol B (7-xylosyl-10-Deacetylpaclitaxel B) is a paclitaxel derivative derived from T. cuspidate. 7-Xylosyl-10-Deacetyltaxol B has anti-tumor activity and inhibits the growth of S180 sarcoma .

HY-N14191

Malonylniphimycin	Microorganisms Antibiotics Cyclopeptides Source Classification	Antibiotic Bacterial Fungal
Malonylniphimycin is a macrolide antibiotic found in Streptomyces str. hygroscopicus B-7. Malonylniphimycin is resistant to Gram-positive bacteria, fungi and yeasts .

HY-N0235R

Bakuchiol (Standard) (S)-(+)-Bakuchiol (Standard)	Structural Classification Monophenols Leguminosae Phenols Psoralea corylifolia L. Plants Source Classification	Carboxylesterase (CES) Reference Standards p38 MAPK Autophagy UGT
Bakuchiol (Standard) is the analytical standard of Bakuchiol. This product is intended for research and analytical applications. Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-N0372R

Licochalcone A (Standard)	Structural Classification Chalcones Flavonoids Leguminosae Plants Glycyrrhiza uralensis Fisch. Source Classification	Reference Standards Autophagy
Licochalcone A (Standard) is the analytical standard of Licochalcone A. This product is intended for research and analytical applications. Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and Ki values lower than 5 μM) .

HY-N14662

Griseolic acid B 7′-Desoxygriseolic acid	Microorganisms Ketones, Aldehydes, Acids Source Classification	Phosphodiesterase (PDE)
Griseolic acid B (7′-Desoxygriseolic acid) has the activity of inhibiting cyclic adenosine monophosphate (cAMP) phosphodiesterase [EC 3.1.4.17] with an IC₅₀ of 0.16 μM .

HY-N0859R

Schisanhenol (Standard) Schizanhenol (Standard); Gomisin-K3 (Standard)	Structural Classification Monophenols Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Source Classification	UGT Reference Standards Cholinesterase (ChE) Tau Protein SOD Sirtuin
Schisanhenol (Standard) (Schizanhenol (Standard)) is the analytical standard of Schisanhenol (HY-N0859). This product is intended for research and analytical applications. Schisanhenol, a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration.

Cat. No.	Product Name	Chemical Structure

HY-B0511S3

Biotin-13C5
Biotin- ¹³C₅ (Vitamin B7- ¹³C₅) is ¹³C labeled Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .

HY-B0511S

Biotin-d2-1
Biotin-d₂-1 is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.

HY-B0511S2

Biotin-d2
Biotin-d₂ is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.

HY-B0511S1

rel-Biotin-d4
rel-Biotin-d₄ is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.

HY-137522S

Zidovudine O-β-D-glucuronide-d3 sodium

Zidovudine O-β-D-glucuronide-d₃ sodium (3'-Azido-3'-deoxythymidine β-D-glucuronide-d₃ sodium) is a deuterium labeled Zidovudine O-β-D-glucuronide sodium (HY-137522). Zidovudine O-β-D-glucuronide (3'-Azido-3'-deoxythymidine β-D-glucuronide) sodium is the glucuronide conjugate and metabolite of Zidovudine (HY-17413), which can be used to detect UGT2B7 activity. As a substrate, Zidovudine O-β-D-glucuronide sodium undergoes deconjugation via hydrolysis by immobilized β-glucuronidase to produce Zidovudine .

Host:	Rat (1) Mouse (24) Armenian hamster (1) Rabbit (21)
Reactivity:	Human (43) Rat (14) Mouse (18) Monkey (4) Rabbit (4) Dog (2)
Application:	IHC-P (22) ICC/IF (20) mIHC (1) IF-Tissue (1) IP (4) IHC-F (2) WB (23) FC (26) ELISA (19)
Isotype:	IgG (24) IgG1 (10) IgG2a (3) IgG/Kappa (1) IgG2b (5)
Conjugation:	FITC (1) PE (2) Non-conjugated (44) Biotin (32)
Clonality:	Polyclonal (1) Monoclonal (33) Monoclonal Antibody (1) Recombinant (12)
Modification:	Unmodified (35)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810369

	B7H4 Antibody (YA9689) B7 family member, H4, B7 H4, B7 homolog 4, B7 superfamily member 1, B7 superfamily, member 1, B7-H4, B7h.5, B7h4, B7S1, B7x	WB, ICC/IF	Human, Mouse, Rat
	B7H4 Antibody (YA9689) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to B7H4.

HY-P84266

	CD80 Antibody (YA3963) B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1	IHC-P, FC, ELISA	Human, Mouse, Rat, Rabbit
	CD80 Antibody (YA3963) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD80.

HY-P84266A

	CD80 Antibody (YA3963)(PBS only) B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1	IHC-P, FC, ELISA	Human, Mouse, Rat, Rabbit
	CD80 Antibody (YA3963) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD80.

HY-P85804

	CD80 Antibody (YA5496) T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7; CD antigen CD80;	FC, ELISA	Human
	CD80 Antibody (YA5496) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD80.

HY-P81609

	B7H6 Antibody (YA1354) B7-H6; NCR3LG1; B7 Homolog 6	WB, ICC/IF, IP, FC	Human
	B7H6 Antibody (YA1354) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H6.

HY-P81668

	CD80 Antibody (YA1413) CD80; CD28LG; CD28LG1; LAB7; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7; CD antigen CD80	FC, ELISA	Human
	CD80 Antibody (YA1413) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD80.

HY-P85094

	CD80 Antibody (YA4786) CD80; CD28LG; CD28LG1; LAB7; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7; CD antigen CD80	IHC-P, ICC/IF, ELISA	Human
	CD80 Antibody (YA4786) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD80.

HY-P83711M

	Armenian Hamster Anti-Mouse CD80 Antibody (PE) (YA3448) T-lymphocyte activation antigen CD80; Cd80; Activation B7-1 antigen; B7	FC	Mouse
	Armenian Hamster Anti-Mouse CD80 Antibody (PE) (YA3448) is an Armenian hamster-derived and phycoerythrin (PE) IgG monoclonal antibody, targeting to CD80.

HY-P86682

	CD86 Antibody (YA6374) CD28LG2; FUN1; LAB72; Activation B7 2 antigen; Activation B7-2 antigen 3; CD86_HUMAN; Activation B7-2 antigen; Activation B72 antigen; B lymphocyte activation antigen B7 2; B lymphocyte activation antigen B72; B-lymphocyte activation antigen B7-2 2; B-lymphocyte activation antigen B7-2; B7 2; B7 2 antigen; B7; B7-2; B7.2; B70; B72 antigen; BU63; CD 86; CD28 antigen ligand 2 2; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86 antigen(CD28 antigen ligand 2, B7-2 antigen) 1, 2; CD86 antigen; CD86 molecule; CLS1; CTLA 4 counter receptor B7 2; CTLA 4 counter receptor B7.2; CTLA-4 counter-receptor B7.2 2, 3; CTLA4 counter receptor B72; Early T-cell costimulatory molecule 1; ETC-1; FUN 1; LAB72; Ly-58; Ly58; MB7; MB7-2; Membrane glycoprotein; MGC34413; T lymphocyte activation antigen CD86; T-lymphocyte activation antigen CD86; TS/A-2.	FC, WB, ICC/IF	Human
	CD86 Antibody (YA6374) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

HY-P86682A

	CD86 Antibody (YA6374)(PBS only) CD28LG2; FUN1; LAB72; Activation B7 2 antigen; Activation B7-2 antigen 3; CD86_HUMAN; Activation B7-2 antigen; Activation B72 antigen; B lymphocyte activation antigen B7 2; B lymphocyte activation antigen B72; B-lymphocyte activation antigen B7-2 2; B-lymphocyte activation antigen B7-2; B7 2; B7 2 antigen; B7; B7-2; B7.2; B70; B72 antigen; BU63; CD 86; CD28 antigen ligand 2 2; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86 antigen(CD28 antigen ligand 2, B7-2 antigen) 1, 2; CD86 antigen; CD86 molecule; CLS1; CTLA 4 counter receptor B7 2; CTLA 4 counter receptor B7.2; CTLA-4 counter-receptor B7.2 2, 3; CTLA4 counter receptor B72; Early T-cell costimulatory molecule 1; ETC-1; FUN 1; LAB72; Ly-58; Ly58; MB7; MB7-2; Membrane glycoprotein; MGC34413; T lymphocyte activation antigen CD86; T-lymphocyte activation antigen CD86; TS/A-2.	FC, WB, ICC/IF	Human
	CD86 Antibody (YA6374) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

HY-P87006

	PD-L1 Antibody (YA6699) B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody;	WB, IHC-P, mIHC	Mouse
	PD-L1 Antibody (YA6699) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P81534

	CD276 Antibody (YA1279) CD276; B7H3; PSEC0249; CD276 antigen; 4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD276	IHC-P	Human
	CD276 Antibody (YA1279) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD276.

HY-P86684

	PD-L1 Antibody (YA6376) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	WB, IHC-P, IHC-F, IF-Tissue, ICC/IF	Human
	PD-L1 Antibody (YA6376) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751

	PD-L1 Antibody (YA6443) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P89400M

	CD274/PD-L1 Antibody (PE) (YA8851) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751A

	PD-L1 Antibody (YA6443)(PBS only) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P85833

	CD276/B7H3 Antibody (YA5525) CD276; B7H3; PSEC0249; CD276 antigen; 4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD276	WB, ICC/IF, ELISA	Human, Mouse, Rat
	CD276/B7H3 Antibody (YA5525) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

HY-P81534A

	CD276 Antibody (YA1279)(PBS only) CD276; B7H3; PSEC0249; CD276 antigen; 4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD276	IHC-P	Human
	CD276 Antibody (YA1279) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD276.

HY-P85087

	CD276/B7H3 Antibody (YA4779) CD276; B7H3; PSEC0249; CD276 antigen; 4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD antigen CD276	WB, IHC-P, ICC/IF, FC, ELISA	Human
	CD276/B7H3 Antibody (YA4779) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

HY-P81184

	CD80 Antibody (YA3386) Activation B7-1 antigen; B lymphocyte activation antigen B7; B7; B7-1; B7-1 antigen; BB1; CD28 antigen ligand 1; CD28LG; CD28LG1; CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); CD80 antigen; CD80 molecule; CD80_HUMAN; Costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; LAB7; T-lymphocyte activation antigen CD80; CD80_RAT.	WB, ICC/IF, FC	Human, Mouse
	CD80 Antibody (YA3386) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to CD80.

HY-P84983

	CD276/B7H3 Antibody (YA4675) CD276; B7H3; PSEC0249; CD276 antigen; 4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD antigen CD276; CD276 nanobody; B7H3 nanobody;	ELISA	Human
	CD276/B7H3 Antibody (YA4675) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

HY-P84982

	PD-L1 Antibody (YA4674) 1 Publications Verification Programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD antigen CD274; CD274 nanobody; PD-L1 nanobody;	WB	Human
	PD-L1 Antibody (YA4674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P81427

	B7H4 Antibody (YA1172) B7X; B7H4; B7S1; B7-H4; B7h.5; VCTN1; PRO1291	IHC-P	Human
	B7H4 Antibody (YA1172) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H4.

HY-P81427A

	B7H4 Antibody (YA1172)(PBS only) B7X; B7H4; B7S1; B7-H4; B7h.5; VCTN1; PRO1291	IHC-P	Human
	B7H4 Antibody (YA1172) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H4.

HY-P84637

	CD276/B7H3 Antibody (YA4334) B7H3; B7-H3; 4Ig-B7-H3; CD276	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat, Rabbit, Monkey
	CD276/B7H3 Antibody (YA4334) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD276/B7H3.

HY-P84637A

	CD276/B7H3 Antibody (YA4334)(PBS only) B7H3; B7-H3; 4Ig-B7-H3; CD276	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat, Rabbit, Monkey
	CD276/B7H3 Antibody (YA4334) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD276/B7H3.

HY-P81706

	B7H2/ICOSL Antibody (YA1451) inducible T-cell co-stimulator ligand; B7H2; GL50; B7-H2; B7RP1; CD275; ICOSL; LICOS; B7RP-1; ICOS-L	FC, ELISA	Human
	B7H2/ICOSL Antibody (YA1451) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H2/ICOSL.

HY-P83319

	B7H3/ICOSL Antibody (YA3064) inducible T-cell co-stimulator ligand; B7H2; GL50; B7-H2; B7RP1; CD275; ICOSL; LICOS; B7RP-1; ICOS-L	WB, IP	Human
	B7H3/ICOSL Antibody (YA3064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H3/ICOSL.

HY-P83319A

	B7H3/ICOSL Antibody (YA3064)(PBS only) inducible T-cell co-stimulator ligand; B7H2; GL50; B7-H2; B7RP1; CD275; ICOSL; LICOS; B7RP-1; ICOS-L	WB, IP	Human
	B7H3/ICOSL Antibody (YA3064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H3/ICOSL.

HY-P810493

	B7H4 Antibody (YA9786)	WB, IHC-F, IHC-P, ICC/IF	Human
	B7H4 Antibody (YA9786) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to B7H4.

HY-P86999

	Olig3 Antibody (YA6692) "Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_HUMAN antibody; "Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_HUMAN antibody; Oligo3 antibody; Oligodendrocyte lineage transcription factor 3 antibody; Oligodendrocyte specific bHLH transcription factor 3 antibody; Oligodendrocyte transcription factor 3 antibody; "	WB, ICC/IF, IHC-P	Human, Mouse
	Olig3 Antibody (YA6692) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Olig3.

HY-P84842

	PD-L1 Antibody (YA4539) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P84842A

	PD-L1 Antibody (YA4539)(PBS only) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P86649

	CD86 Antibody (YA6341) T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD antigen CD86;	WB, IHC-P, ICC/IF, ELISA	Mouse
	CD86 Antibody (YA6341) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

HY-P88272

	CYP2B6 (Cytochrome P450 2B6) Antibody (YA7956) CPB6; CYP2B; CYP2B7; CYP2B7P; CYPIIB6; EFVM; IIB1; P450	IHC-P, ICC/IF, FC	Human, Dog, Rat, Monkey, Mouse
	CYP2B6 (Cytochrome P450 2B6) Antibody (YA7956) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CYP2B6 (Cytochrome P450 2B6).

HY-P88272A

	CYP2B6 (Cytochrome P450 2B6) Antibody (YA7956)(PBS only) CPB6; CYP2B; CYP2B7; CYP2B7P; CYPIIB6; EFVM; IIB1; P450	IHC-P, ICC/IF, FC	Human, Dog, Rat, Monkey, Mouse
	CYP2B6 (Cytochrome P450 2B6) Antibody (YA7956) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CYP2B6 (Cytochrome P450 2B6).

HY-P80609

	CD86 Antibody 3 Publications Verification CD86; CD28LG2; T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD antigen CD86	WB, IHC-P, ICC/IF, IP, FC	Human, Rat
	CD86 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CD86.

HY-P84312

	CD86 Antibody (YA4009) B70; B7-2; LAB72; CD28LG2; MGC34413; CD86	WB, ELISA	Human
	CD86 Antibody (YA4009) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD86.

HY-P84312A

	CD86 Antibody (YA4009)(PBS only) B70; B7-2; LAB72; CD28LG2; MGC34413; CD86	WB, ELISA	Human
	CD86 Antibody (YA4009) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD86.

HY-P81839

	PD-L2 Antibody (YA1584) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	WB	Human, Rat
	PD-L2 Antibody (YA1584) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

HY-P81603

	PD-L2 Antibody (YA1348) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	FC, ELISA	Human
	PD-L2 Antibody (YA1348) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

HY-P88308

	TSPAN7 Antibody (YA7992) A15; CCG-B7; CD231; DXS1692E; MRX58; MXS1; TALLA-1; TM4SF2; TM4SF2b	IHC-P	Human, Mouse, Rat
	TSPAN7 Antibody (YA7992) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TSPAN7.

HY-P81839A

	PD-L2 Antibody (YA3391) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273; PD L2; PDL2	WB, ICC/IF, FC, ELISA	Human, Mouse, Rat
	PD-L2 Antibody (YA3391) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L2.

HY-P84941

	HLA Class 1 ABC Antibody (YA4638) Antigen Presenting Molecule antibody; Cw1701 antibody; D6S204 antibody; FLJ27082 antibody; HLA A antibody; HLA B antibody; HLA C antibody; HLA class 1 A antibody; HLA class 1 B antibody; HLA class 1 C antibody; HLA JY3 antibody; HLAA antibody; HLAB antibody; HLAC antibody; HLC C antibody; Human Leucocyte Antigen C antibody; Major Histocompatibility Complex Class I A antibody; Major Histocompatibility Complex Class I B antibody; Major Histocompatibility Complex Class I C antibody; Major histocompatibility complex, class I, A + B + C antibody; MHC class I antigen A1 antibody; MHC Class I Antigen antibody; MHC class I antigen B7 antibody; MHC class I antigen Cw1 antibody; MHC class I HLA A antibody; MHC class I HLA B antibody; MHC class I HLA C antibody; MHC HLA ABC antibody; PSORS1 antibody	ICC/IF, FC	Human
	HLA Class 1 ABC Antibody (YA4638) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA Class 1 ABC.

HY-P83710M

	Rat Anti-Mouse CD86 Antibody (FITC)(YA3447) T-lymphocyte activation antigen CD86; Cd86; Activation B7-2 antigen; Early T-cell costimulatory molecule 1; ETC-1	FC	Mouse
	Rat Anti-Mouse CD86 Antibody (FITC)(YA3447) is a rat-derived and fluorescein isothiocyanate (FITC) IgG2a monoclonal antibody, targeting to CD86.

HY-P88308A

	TSPAN7 Antibody (YA7992)(PBS only) A15; CCG-B7; CD231; DXS1692E; MRX58; MXS1; TALLA-1; TM4SF2; TM4SF2b	IHC-P	Human, Mouse, Rat
	TSPAN7 Antibody (YA7992) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TSPAN7.

HY-P81839AA

	PD-L2 Antibody (YA3391)(PBS only) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273; PD L2; PDL2	WB, ICC/IF, FC, ELISA	Human, Mouse, Rat
	PD-L2 Antibody (YA3391) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-137522

Zidovudine O-β-D-glucuronide sodium 3'-Azido-3'-deoxythymidine β-D-glucuronide sodium		Azide
Zidovudine O-β-D-glucuronide (3'-Azido-3'-deoxythymidine β-D-glucuronide) sodium is the glucuronide conjugate and metabolite of Zidovudine (HY-17413), which can be used to detect *UGT2B7* activity. As a substrate, Zidovudine O-β-D-glucuronide sodium undergoes deconjugation via hydrolysis by immobilized β-glucuronidase to produce Zidovudine .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (60) Rhesus Macaque (12) Rat (16) Mouse (23) Cynomolgus (18) Rabbit (3) Canine (2)
Tag:	His (76) Tag Free (1) Avi (29) Myc (1) Flag (1) Fc (56)
Source:	HEK293 (130) CHO (2)

B7

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products